Publications
2019
. Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. (Abstract ID B117).
Read More > AACR-NCI-EORTC Poster. Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor. The 26th Annual Scientific Retreat | Prostate Cancer Foundation.
Read More > Prostate Cancer Foundation Annual Retreat Poster. EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. European Society of Medical Oncology (ESMO) 2019 Congress. (Abstract ID 503P).
Read More > European Society of Medical Oncology 2019 Congress Poster. Next generation N-terminal domain androgen receptor inhibitor with improved potency and metabolic stability in castration-resistant poster cancers models. Genitourinary Cancers Symposium 2019. (Abstract# MP34-04).
Read More > American Urological Association Poster. Next generation N-terminal domain androgen receptor inhibitor with improved potency and metabolic stability in castration-resistant poster cancers models. Genitourinary Cancers Symposium 2016. (Abstract# 220).
Read More > American Association for Cancer Research Poster